Viatris continues its preparations for phase 2 of its strategic plan by announcing the appointment of theodora "doretta" mistras as chief financial officer, effective march 1, 2024, and philippe martin as chief r&d officer

Company thanks sanjeev narula for his role in the successful execution of viatris' phase 1 strategy; narula will support a smooth cfo transition prior to his departure on march 1, 2024 pittsburgh , dec. 15, 2023 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, today announced that, as it prepares to enter phase 2 of its strategic plan, theodora "doretta" mistras has been appointed chief financial officer (cfo) effective march 1, 2024, and philippe martin has been appointed chief r&d officer with immediate effect. current viatris cfo sanjeev narula, who helped the company successfully execute its phase 1 strategy, will work closely with mistras to support a smooth transition and will then depart the company on march 1, 2024.
VTRS Ratings Summary
VTRS Quant Ranking